These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 11469460

  • 21. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.
    Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA.
    Ann Rheum Dis; 2005 Mar; 64(3):444-8. PubMed ID: 15286009
    [Abstract] [Full Text] [Related]

  • 22. Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease.
    Souza A, da Silva LM, Oliveira FR, Roselino AM, Louzada-Junior P.
    Lupus; 2009 Mar; 18(3):223-9. PubMed ID: 19213860
    [Abstract] [Full Text] [Related]

  • 23. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
    Magalhães MB, da Silva LM, Voltarelli JC, Donadi EA, Louzada-Junior P.
    Scand J Rheumatol; 2007 Mar; 36(6):442-7. PubMed ID: 18092265
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Hyperprolactinemia in systemic lupus erythematosus. A prospective study of 38 cases].
    Smiti Khanfir M, Ben Ghorbel I, Feki M, Lamloum M, Mebazaa A, Miled M, Houman MH.
    Tunis Med; 2004 Jun; 82(6):512-5. PubMed ID: 15517949
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.
    Zandman-Goddard G, Blank M, Langevitz P, Slutsky L, Pras M, Levy Y, Shovman O, Witte T, Doria A, Rovensky J, Shoenfeld Y.
    Ann Rheum Dis; 2005 Dec; 64(12):1698-702. PubMed ID: 16014675
    [Abstract] [Full Text] [Related]

  • 28. Anti-CD43 and anti-galectin-1 autoantibodies in patients with systemic lupus erythematosus.
    Montiel JL, Monsiváis-Urenda A, Figueroa-Vega N, Moctezuma JF, Burgos-Vargas R, González-Amaro R, Rosenstein Y.
    Scand J Rheumatol; 2010 Dec; 39(1):50-7. PubMed ID: 20132071
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study.
    Dhir V, Singh AP, Aggarwal A, Naik S, Misra R.
    Lupus; 2009 Aug; 18(9):785-91. PubMed ID: 19578102
    [Abstract] [Full Text] [Related]

  • 31. Autoantibody profile in the sera of women with hyperprolactinemia.
    Buskila D, Berezin M, Gur H, Lin HC, Alosachie I, Terryberry JW, Barka N, Shen B, Peter JB, Shoenfeld Y.
    J Autoimmun; 1995 Jun; 8(3):415-24. PubMed ID: 7576002
    [Abstract] [Full Text] [Related]

  • 32. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions.
    Tan Y, Yu F, Yang H, Chen M, Fang Q, Zhao MH.
    Hum Immunol; 2008 Dec; 69(12):840-4. PubMed ID: 18852001
    [Abstract] [Full Text] [Related]

  • 33. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus.
    Husebye ES, Sthoeger ZM, Dayan M, Zinger H, Elbirt D, Levite M, Mozes E.
    Ann Rheum Dis; 2005 Aug; 64(8):1210-3. PubMed ID: 15708887
    [Abstract] [Full Text] [Related]

  • 34. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
    Jimenez-Boj E, Kedersha N, Tohidast-Akrad M, Karlhofer FM, Stummvoll G, Zimmermann C, Ulrich W, Guiducci S, Hoefler E, Aringer M, Schett G, Matucci-Cerinic M, Smolen JS, Steiner G.
    Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
    [Abstract] [Full Text] [Related]

  • 35. Reduced anti-TNFalpha autoantibody levels coincide with flare in systemic lupus erythematosus.
    Sjöwall C, Ernerudh J, Bengtsson AA, Sturfelt G, Skogh T.
    J Autoimmun; 2004 Jun; 22(4):315-23. PubMed ID: 15120755
    [Abstract] [Full Text] [Related]

  • 36. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
    Morel J, Roubille C, Planelles L, Rocha C, Fernandez L, Lukas C, Hahne M, Combe B.
    Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
    [Abstract] [Full Text] [Related]

  • 37. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus.
    Morgan PE, Sturgess AD, Davies MJ.
    Arthritis Rheum; 2005 Jul; 52(7):2069-79. PubMed ID: 15986354
    [Abstract] [Full Text] [Related]

  • 38. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK.
    Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
    [Abstract] [Full Text] [Related]

  • 39. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity.
    Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F.
    Lupus; 2001 May; 10(8):554-61. PubMed ID: 11530997
    [Abstract] [Full Text] [Related]

  • 40. Prolactin in systemic lupus erythematosus.
    Pauzner R, Urowitz MB, Gladman DD, Gough JM.
    J Rheumatol; 1994 Nov; 21(11):2064-7. PubMed ID: 7869311
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.